Phase I study of oral capecitabine (Xeloda) as a radiation enhancer in locally unresectable, residual, or recurrent colorectal cancer localized in the pelvis
Latest Information Update: 28 Aug 2015
At a glance
- Drugs Capecitabine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 15 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 13 Jul 2007 New trial record.